Kyowa Hakko Kirin Co., Limited

Kyowa Hakko Kogyo Co., Ltd.

Other

Millennium Pharmaceuticals Limited

Tetsuji Ohno

Yuji Nomoto

Masamori Sugawara

Takao Nakajima

Shin-ichi Uchida

Yoshisuke Nakasato

Noriaki Uesaka

Etsuo Ohshima

Jay R Luly

Fumio Suzuki

Geraldine C B Harriman

Kenji Ohmori

Shomir Ghosh

Kenneth Gordon Carson

Amy M Elder

Soichiro Sato

Karen M Mattia

Haruhiko Manabe

Michio Ichimura

Hiroshi Tanaka

Takashi Sawada

Geraldine C Harriman

Tomoyuki Nishikawa

Tadafumi Tamura

Hidee Ishii

Kyoichiro Iida

Osamu Kotera

Hiroki Sone

Kazuhiro Kubo

Hidetomo Imase

Takeshi Kuroda

Etsuo Oshima

Koji Yanagawa

Hiroshi Tsumuki

Hiroshi Nakajima

Takashi Kawakita

Tohru Matsuzaki

Toshimi Kanai

Hiroshi Umehara

Rie Koike

Yuichi Fukuda

Yushi Kitamura

Keisuke Kimpara

Toshihiro Seike

Satoshi Kaneko

Hisashi Hosoe

Naoto Osakada

Keishi Katayama

Atsuko Mizutani

Ikufumi Yoshitake

Misato Tomuro

Toshihide Ikemura

Kiyotoshi Mori

Hajime Kashima

Kuniyuki Kishikawa

Mariko Osakada

Yusuke Yamada

Shin-Ichi Uchida

Geraldine CB Harriman

The present invention provides a nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof having an inhibitory effect on the production of kynurenine, represented by formula (I): 

Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

Chemokine receptor antagonists and methods of use

Method of treating central nervous systems disease by administering wherein n is an integer of from 0 to 3; Ris a 5-membered aromatic heterocyclic group containing at least one oxygen atom; Ris &#x2014;COR(wherein Ris aryl); Ris hydrogen or lower alkyl; and Rrepresents cycloalkyl, aryl, aralkyl, alicyclic heterocyclic group, aromatic heterocyclic group, alicyclic hetocyclic-alkyl, or aromatic heterocyclic-alkyl, and R, R, Rand Rare individually optionally substituted.

Thiazole derivatives

Chemokine receptor antagonists and methods of use thereof

Wherein n is an integer of from 0 to 3; Ris a 5-membered aromatic heterocyclic group containing at least one oxygen atom; Ris &#x2014;COR(wherein Ris aryl); Ris hydrogen or lower alkyl; and Rrepresents cycloalkyl, aryl, aralkyl, alicyclic heterocyclic group, aromatic heterocyclic group, alicyclic hetocyclic-alkyl, or aromatic heterocyclic-alkyl, and R, R, Rand Rare individually optionally substituted. 

A CB2 receptor modulator comprising an imidazole derivative represented by the general formula (I): [wherein, Rrepresents optionally substituted lower alkyl or the like; Rrepresents optionally substituted cycloalkyl or the like; Rrepresents optionally substituted aryl or the like; and n represents an integer of 0 to 3] or a pharmaceutically acceptable salt thereof as an active ingredient, and the like are provided.

Imidazole derivatives

Chemokine receptor antagonists and methods of use therefor

The present invention provides 2-aminoquinazoline derivatives represented by formula (I): 

2-aminoquinazoline derivatives

(Wherein n is an integer of from 0 to 3; Ris substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, or a substituted or unsubstituted aromatic heterocyclic group; Ris halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, &#x2014;COR, or the like; Rand Rmay be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl, &#x2014;COR, or the like) For example, provided are adenosine Areceptor antagonists comprising, as the active ingredient, a thiazole derivative represented by a general formula (I), or a pharmaceutically acceptable salt thereof, and the like. 

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof 

Derivatives of benzofuran or benzodioxazole compounds

Derivatives of benzofuran or benzodioxole

Growing community of inventors

Shizuoka, Japan

Yoshisuke Nakasato